GERI Study: Gathering Evidence and Real-World Insights in Osteoarthritis Management with Undenatured Type II Collagen

Abstract Background: Osteoarthritis (OA) is a progressive joint disorder commonly affecting older adults and is increasingly prevalent in India. While conventional therapies offer symptomatic relief, they do not address the underlying disease process. Undenatured type II collagen (UC-II), a symptomatic slow-acting drug (SYSADOA), has emerged as a promising adjunct in OA management due to its ability to modulate immune response and improve joint function. Objective: The gathering evidence and real-world insights (GERI) study aimed to assess the knowledge, attitudes, and practices (KAP) of Indian orthopedic healthcare providers (HCPs) regarding the clinical use of UC-II in OA management. Materials and Methods: A cross-sectional, questionnaire-based study was conducted among 416 orthopedic HCPs across India. The survey evaluated OA prevalence, treatment strategies, UC-II efficacy and safety, and quality-of-life outcomes using structured KAP questionnaires. Results: The majority of HCPs (95.1%) favored collagen supplementation, with 61% preferring UC-II. Over 74% recommended UC-II alongside pharmacologic therapy. UC-II was most often initiated in early OA, with 60.2% reporting symptom improvement within one to three months. It was rated superior to glucosamine and chondroitin in adherence, efficacy, and tolerability. Additionally, 74.5% observed a reduction in nonsteroidal anti-inflammatory drug use. Physical therapy and weight management were the most commonly recommended adjuncts. Conclusion: The GERI study highlights strong clinical acceptance of UC-II among Indian orthopedic HCPs as an effective and well-tolerated adjunct in OA management. Its early use, combined with lifestyle interventions, may offer sustainable benefits in improving patient outcomes and reducing reliance on conventional drugs.